Statin-associated neuromyotoxicity
Abstract
The sequelae of cardiovascular disease contribute significantly to morbidity and mortality in developed nations. As a class, the statins have been shown to measurably reduce the burden of atherosclerotic illness. However, muscle- and, more recently, nerve-related toxicity have emerged as potential complications leading to treatment withdrawal. Generally, the myopathic signs and symptoms of tenderness, myalgias, cramping and elevated serum creatine kinase (CK) activity are fully reversible after drug discontinuation. Growing evidence suggests that latent or previously minimal symptomatic muscle disease may predispose to the development of myopathy. Less information is available regarding the natural history of the sensorimotor neuropathy, but it appears to be less reversible if large fiber function is clinically manifest. Pathophysiologic clues regarding the potential causes of statin myopathy with or without neuropathy are discussed with particular attention paid to the implications of disrupted mevalonate metabolism. For example, secondary defects in isoprenoid biosynthesis are expected to impair the production of a variety of intermediaries such as dolichols, which are crucial for N-linked glycosylation; geranylgeranyl pyrophosphate, which is necessary for coenzyme Q(10) and G-protein synthesis; farnesyl-pyrophosphate, which facilitates the endoproteolytic cleavage and maturation of prelamin A and modifies B-type lamins and G-proteins; and isopentenylpyrophosphate, which is involved in a nucleoside modification of selenocysteinyl-tRNA and thus indirectly related to the synthesis of all selenoproteins (approximately 35). The nature of statin neuromyotoxicity remains unresolved; however, investigating the cellular corollaries of deranged isoprenoid metabolism may uncover clues that lead to a more complete understanding of the elusive pathophysiology.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Cited by
Sorted by citations
The Role of Coenzyme Q10 in Statin-Associated Myopathy
Marcoff, L., & Thompson, P. D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.049 · Cited by 537 · see citing works
Tarnopolsky, M. A. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.05.001 · Cited by 158 · see citing works
Self-citationSaku, K., Zhang, B., Noda, K., & The PATROL Trial Investigators (2011) · Circulation Journal · doi:10.1253/circj.cj-10-1281 · Cited by 130 · see citing works
Terblanche, M., Almog, Y., Rosenson, R. S., Smith, T. S., & Hackam, D. G. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70439-x · Cited by 117 · see citing works
Myotoxicity associated with lipid-lowering drugs
Baer, A. N., & Wortmann, R. L. (2006) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328010c559 · Cited by 93 · see citing works
Current Practices of AAHKS Members in the Treatment of Adult Osteonecrosis of the Femoral Head
McGrory, B. J., York, S. C., Iorio, R. R., et al. (2007) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.f.00302 · Cited by 81 · see citing works
Physiogenomic association of statin‐related myalgia to serotonin receptors
Ruaño, G., Thompson, P. D., Windemuth, A., Seip, R. L., Dande, A. S., Sorokin, A., Kocherla, M., Smith, A. P., Holford, T. R., & Wu, A. H. B. (2007) · Muscle & Nerve · doi:10.1002/mus.20871 · Cited by 70 · see citing works
Clinical Use of Creatine in Neuromuscular and Neurometabolic Disorders
Tarnopolsky, M. A. (2007) · Subcellular Biochemistry · doi:10.1007/978-1-4020-6486-9_10 · Cited by 67 · see citing works
“Statin-related muscle symptoms affect 3 to 5% of the population, and some of the pathology may be due to mitochondrial dysfunction ( Baker and Tarnopolsky, 2001, 2003, 2005 ).”
BackgroundSelf-citationFeng, Q., Wilke, R. A., & Baye, T. M. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.11 · Cited by 64 · see citing works
Creatine and Creatine Kinase in Health and Disease
Salomons, G. S., & Wyss, M. (2007) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-1-4020-6486-9 · Cited by 67 · see citing works
Tierney, E. F., Thurman, D. J., Beckles, G. L., & Cadwell, B. L. (2012) · Journal of Diabetes · doi:10.1111/1753-0407.12013 · Cited by 57 · see citing works
Christopher‐Stine, L. (2006) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000245730.25383.97 · Cited by 57 · see citing works
Momi, S., Impagnatiello, F., Guzzetta, M., Caracchini, R., Guglielmini, G., Olivieri, R., Monopoli, A., & Gresele, P. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.05.014 · Cited by 48 · see citing works
Radcliffe, K. A., & Campbell, W. W. (2008) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-008-0011-4 · Cited by 45 · see citing works
Ezetimibe-related myopathy: A systematic review
Slim, H. B., & Thompson, P. D. (2008) · Journal of clinical lipidology · doi:10.1016/j.jacl.2008.08.430 · Cited by 30 · see citing works
Mor, A., Wortmann, R. L., Mitnick, H. J., & Pillinger, M. H. (2011) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2011.01.005 · Cited by 28 · see citing works
Robman, L. D. (2008) · Clinical Interventions in Aging · doi:10.2147/cia.s2748 · Cited by 26 · see citing works
“…size required, diffi cul-ties in having a placebo group and possible side effects of statins in subjects with normal cholesterol (Klein and Klein 2004; Baker and Tarnopolsky 2005; Lamperti et al 2005), a growing body of evidence and confl icting results from the observational and case-control…”
Eicosapentaenoic acid attenuates statin-induced ER stress and toxicity in myoblast
Ohta, M., Kawano, H., Notsu, T., Naba, H., & Imada, K. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.06.111 · Cited by 19 · see citing works
Exercise Testing in Metabolic Myopathies
Tarnopolsky, M. A. (2011) · Physical Medicine and Rehabilitation Clinics of North America · doi:10.1016/j.pmr.2011.11.011 · Cited by 18 · see citing works
Self-citationAssociation Between Statin Use and Bell’s Palsy: A Population-Based Study
Hung, S., Wang, L., Lin, H., et al. (2014) · Drug Safety · doi:10.1007/s40264-014-0212-5 · Cited by 16 · see citing works
“However, there are also reports in which statins seem to be associated with several neurologic disorders [12–15].”
BackgroundMedikamenteninduzierte Myopathien
Finsterer, J. (2006) · Der Nervenarzt · doi:10.1007/s00115-006-2080-4 · Cited by 13 · see citing works
“die Isoprenoidbiosynthese, wodurch Dolichole, Geranyl-Geranyl-Pyrophosphat, das für die Generierung von Co-Q und G-Protein notwendig ist, Farnesyl-Pyrophosphat und Iso-pentenyl-Pyrophosphat vermindert werden [8].”
BackgroundInfluentialErectile dysfunction and statins: The assorted view of preponderance
Al-Kuraishy, H. M., Al-Gareeb, A. I., & Al-Maiahy, T. J. (2020) · Asian Pacific Journal of Reproduction · doi:10.4103/2305-0500.281074 · Cited by 12 · see citing works
Influence of Stem Cell Therapy on Statin-induced Myopathy of Skeletal Muscle in Female Rats
... (2012) · Turkish Journal Of Neurology · doi:10.4274/tnd.88709 · Cited by 9 · see citing works
Toxic and Drug-Induced Neuropathies
Cavaletti, G. (2007) · Neurobiology of Disease · doi:10.1016/b978-012088592-3/50082-7 · Cited by 8 · see citing works
Approach to Clinical and Genetic Characterization of Statin-Induced Myopathy
Feng, Q. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-0956-8_5 · Cited by 7 · see citing works
Slade, J. M., Abela, G. S., Rozman, M., McClowry, R. J., Hurley, D., Forbes, S. C., & Meyer, R. A. (2021) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2021.100028 · Cited by 8 · see citing works
“While important for generally reducing major cardiovascular risk factors and events, there are potential deleterious impacts of statins on skeletal muscle function [3].”
Drug‐Induced and Iatrogenic Neurological Disorders
Kompoliti, K., & Horn, S. S. (2007) · Elsevier eBooks · doi:10.1016/b978-141603618-0.10055-4 · Cited by 7 · see citing works
Two Cases of Statin-Induced Rhabdomyolysis Associated with Mononeuropathy
Fadini, G. P., Manzato, E., Crepaldi, C., de Kreutzenberg, S., Tiengo, A., & Avogaro, A. (2010) · Clinical Drug Investigation · doi:10.2165/11535470-000000000-00000 · Cited by 7 · see citing works
Kovacic, S., Habicht, S. D., & Eckert, G. P. (2025) · Journal of Nutritional Science · doi:10.1017/jns.2025.10043 · Cited by 4 · see citing works
[Are statins a therapeutic alternative in sepsis?].
Carrillo-Esper, R., Rivera-Buendía, S., Carrillo-Córdova, J. R., et al. (2008) · PubMed · Cited by 3 · see citing works
The Failure of Vytorin and Statins to Improve Cardiovascular Health: Bad Cholesterol or Bad Theory?
Peskin, B. S., Sim, D., & Carter, M. J. (2008) · Cited by 2 · see citing works
Farouk, A. A., El-Stoohy, F., Ali, S. E.-A., El-Atty, H. K. A., Rashed, L. A., Krysha, N. A., & Mohammed, S. (2012) · Cited by 2 · see citing works
The Great Cholesterol Quandary and Global Consciousness Awakening
Alabdulgader, A. (2023) · World Journal of Cardiovascular Diseases · doi:10.4236/wjcd.2023.1311064 · Cited by 1 · see citing works
Future approaches to reducing low-density lipoprotein cholesterol
Wierzbicki, A. S. (2006) · Future Lipidology · doi:10.2217/17460875.1.4.463 · Cited by 1 · see citing works
“Other suggestions include depletion of intracellular free fatty acids leading to an unfulfilled requirement for the excess uptake of plasma cholesterol, such that patients with hyperfunctional lipoprotein lipase variants (LPL 447X) have a functional deficiency [33] in addition to alterations in intracellular calcium […”
BackgroundNeurovirological Aspects of HIV Infection in the HAART Era
Parveen, Z., Acheampong, E. A., Pomerantz, R. J., & Mukhtār, M. (2014) · ASM Press eBooks · doi:10.1128/9781555815691.ch10
Banach, M. D., Juranek, J. K., & Antczak, J. M. (2015) · Family Medicine & Primary Care Review · doi:10.5114/fmpcr/60395
Statin-Induced Muscle Toxicity
Feng, Q., & Wilke, R. A. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-381510-1.00067-3
Perotti, M., & Costa, L. G. (2014) · Encyclopedia of the Neurological Sciences · doi:10.1016/b978-0-12-385157-4.00254-2
(2006) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32801437a8
Current awareness: Pharmacoepidemiology and drug safety
(2005) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1174
Statin therapy and sex hormones
Chiti, H., Parsamanesh, N., Reiner, Ž., Jamialahmadi, T., & Sahebkar, A. (2023) · Principles of Gender-Specific Medicine · doi:10.1016/b978-0-323-88534-8.00012-2 · Cited by 1 · see citing works
Kawabata, S., Iijima, H., Kanemura, N., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4431608/v1
Kawabata, S., Iijima, H., Kanemura, N., & Murata, K. (2025) · Molecular Neurobiology · doi:10.1007/s12035-024-04666-8
- Authors
- Baker, S. K., & Tarnopolsky, M. A.
- Affiliations
- McMaster University Medical Centre (CA)
- Venue
- Drugs of Today
- Publisher
- Portico
- Published
- 2005
- Volume
- 41
- Issue
- 4
- Pages
- 267
- ISSN
- 0025-7656 (ISSN-L)
- 1699-4019
- OpenAlex
- W1968779439
- Cited by
- 42
- References
- 0
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 2 · 2021: 1 · 2020: 1 · 2015: 1 · 2014: 4 · 2012: 6
- FWCI
- 6.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drugs of today (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Health Sciences › Medicine › Neurology › Peripheral Neuropathies and Disorders
- Keywords
- statin-induced myopathy, mevalonate metabolism, isoprenoid biosynthesis, geranylgeranyl pyrophosphate, farnesyl pyrophosphate, dolichol, N-glycosylation, selenoproteins, creatine kinase elevation, muscle toxicity, sensorimotor neuropathy, nuclear lamins, G proteins, coenzyme Q10
- MeSH terms
- Acyl Coenzyme A, Cholesterol, Humans, Mevalonic Acid, Muscular Diseases, Peripheral Nervous System Diseases, Rhabdomyolysis, Terpenes, Ubiquinone, Adverse Drug Reaction Reporting Systems, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
